Monday, January 23, 2017 8:16:32 AM
TORONTO, ON--(Marketwired - Jan 23, 2017) - Easton Pharmaceuticals, Inc. ( OTC PINK : EAPH ) Announces that it has signed a letter of intent to acquire 100% of revenue producing vaporizer manufacturer iBliss Inc., of Toronto, Ontario, Canada.
iBliss Inc. is a tremendously fast growing vaporizer and e-liquids manufacturing company with surging international sales projected to conservatively reach and surpass $15,000,000 per year fairly quickly. iBliss currently generates several millions of dollars in sales with healthy margins in excess of 40%. iBliss has had tremendous growth over the past 3 years of being in business which includes sales throughout North America and recently adding several international markets in Europe, the Middle East and Russia which has it on track to reach $15,000,000 in sales. iBliss possesses in house manufacturing of its own line of e-liquids products in a certified and regulated laboratory. iBliss's sales continue to grow with demand for Vaporizer's and e-liquids surging internationally. The company also intends on launching consumer health related products through its liquids for use in vaporizers, which will also result in substantial growth.
"We are very excited to be entering into this Agreement with Easton. With the support of Easton's management, we will be able to continue our success and rapidly expand our sales internationally and launch our consumer health products through our e-liquids," stated iBliss President, Hung Tran.
The iBliss acquisition is intended to have iBliss operate as a wholly owned subsidiary of Easton and will be separate from Easton's other business segments such it's woman's diagnostics, treatment and natural health products where Easton recently executed a distribution agreement with multi-national pharmaceutical company Gedeon Richter and its Mexican subsidiary company Gedeon Richter Mexico S.A.P.I. de C.V. for Easton / BMV Medica's Gynofit product. The signed letter of intent with iBliss is the first step in its negotiations as both companies work towards finalizing a closed Definitive Agreement in the coming weeks.
https://finance.yahoo.com/news/easton-pharmaceuticals-signs-letter-intent-130000058.html
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM